Our data suggest that this oncogenic driver of T cell leukemia/lymphoma should be thought of as a de novo transcription factor with a set of cancer-associated target genes that is qualitatively different from wild-type STAT5B. The gene discussed is STAT5B; the disease is T-cell leukemia.